Semaglutide is the one peptide on this site with current FDA labels, a deep trial record and a large unregulated side. This page keeps those apart: what each label says, what trials actually tested, and what circulates for vials, microdoses and stacks.
Ask PeptideBlog about any peptide
Quick answer: Labeled semaglutide doses depend on the product. Ozempic (type 2 diabetes) starts at 0.25 mg once weekly and tops out at 2 mg.[2] Wegovy (weight, heart risk, liver disease) starts at 0.25 mg, rises every 4 weeks, and maintains at 1.7 or 2.4 mg, with 7.2 mg allowed for some adults.[1] Tablets run daily: Wegovy 1.5, 4, 9, then 25 mg.[1] No label or trial covers vial mixing, microdoses or stacks.
Figures in this section summarize amounts and schedules reported in published research, prescribing information or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Every studied or reported semaglutide amount at a glance
Three kinds of evidence sit in this table. Label rows are what the FDA approved for a specific product. Trial rows are what researchers gave to volunteers. The last group is what people report using outside both. The label for one product does not transfer to another, so Ozempic and Wegovy get separate rows even though the drug is the same.
Swipe the table sideways to see every column.
| Source or product | Population or use | Route | Amount | Frequency | Duration or steps | Evidence category |
|---|---|---|---|---|---|---|
| FDA-approved labels (as written in the prescribing information) | ||||||
| Ozempic | Adults with type 2 diabetes (also heart and kidney indications) | Subcutaneous | Start 0.25 mg, then 0.5 mg. Maintenance 0.5, 1 or 2 mg. Maximum 2 mg | Once weekly | 0.25 mg for 4 weeks, then at least 4 weeks per step | Prescribing information[2] |
| Wegovy injection, weight | Adults with obesity, or overweight plus a comorbidity; age 12 and up with obesity | Subcutaneous | 0.25, 0.5, 1, 1.7 mg, then maintenance 1.7 or 2.4 mg (2.4 mg recommended) | Once weekly | 4 weeks per step; maintenance from week 17 | Prescribing information[1] |
| Wegovy HD (7.2 mg) | Adults who tolerate 2.4 mg for at least 4 weeks and need more weight reduction | Subcutaneous | Up to 7.2 mg | Once weekly | Only after at least 4 weeks at 2.4 mg | Prescribing information[1][4] |
| Wegovy injection, heart and liver uses | Heart risk: adults with established cardiovascular disease and obesity or overweight. Liver: adults with noncirrhotic MASH, fibrosis F2 to F3 | Subcutaneous | Heart: 2.4 mg recommended, or 1.7 mg. Liver: 2.4 mg, reduce to 1.7 mg if not tolerated | Once weekly | Same 16-week escalation first | Prescribing information[1] |
| Wegovy tablets | Adults with obesity, or overweight plus a comorbidity; heart risk | Oral | 1.5, 4, 9 mg, then 25 mg maintenance | Once daily | 30 days per step; 25 mg from day 91 | Prescribing information[1] |
| Rybelsus tablets (formulation R1) | Adults with type 2 diabetes | Oral | 3 mg, then 7 mg, then 7 or 14 mg | Once daily | 30 days at 3 mg, 30 days at 7 mg, then maintenance | Prescribing information[3] |
| Ozempic tablets (formulation R2) | Adults with type 2 diabetes | Oral | 1.5 mg, then 4 mg, then 4 or 9 mg | Once daily | Same pattern as R1 | Prescribing information[3][6] |
| Studied in trials (arms as published) | ||||||
| STEP 1 | 1,961 adults with overweight or obesity, no diabetes | Subcutaneous | 2.4 mg | Once weekly | 68 weeks | Published human clinical trial (Tier 1)[7] |
| STEP 2 | 1,210 adults with obesity or overweight and type 2 diabetes | Subcutaneous | 2.4 mg and 1.0 mg | Once weekly | 68 weeks | Published human clinical trial (Tier 1)[8] |
| STEP 5 | 304 adults, no diabetes | Subcutaneous | 2.4 mg | Once weekly | 104 weeks | Published human clinical trial (Tier 1)[9] |
| STEP UP | 1,407 adults with obesity, no diabetes | Subcutaneous | 7.2 mg and 2.4 mg | Once weekly | 72 weeks | Published human clinical trial (Tier 1)[10] |
| STEP UP T2D | 512 adults with obesity and type 2 diabetes | Subcutaneous | 7.2 mg and 2.4 mg | Once weekly | 72 weeks | Published human clinical trial (Tier 1)[11] |
| STEP TEENS | 201 adolescents aged 12 to under 18 | Subcutaneous | 2.4 mg | Once weekly | 68 weeks | Published human clinical trial (Tier 1)[20] |
| OASIS 1 | 667 adults with overweight or obesity, no diabetes | Oral | Escalated to 50 mg (not a marketed dose) | Once daily | 68 weeks | Published human clinical trial (Tier 1)[12] |
| OASIS 4 | 307 adults with overweight or obesity, no diabetes | Oral | 25 mg | Once daily | Primary endpoint at week 64 (71-week trial) | Published human clinical trial (Tier 1)[13] |
| SELECT | 17,604 adults 45 and older with cardiovascular disease and BMI 27 or more, no diabetes | Subcutaneous | 2.4 mg | Once weekly | Mean exposure 34.2 months | Published human clinical trial (Tier 1)[14] |
| FLOW | 3,533 adults with type 2 diabetes and chronic kidney disease | Subcutaneous | 1.0 mg | Once weekly | Median follow-up 3.4 years | Published human clinical trial (Tier 1)[15] |
| SUSTAIN-6 | 3,297 adults with type 2 diabetes at high cardiovascular risk | Subcutaneous | 0.5 mg or 1.0 mg | Once weekly | 104 weeks | Published human clinical trial (Tier 1)[16] |
| SUSTAIN FORTE | 961 adults with type 2 diabetes | Subcutaneous | 2.0 mg versus 1.0 mg | Once weekly | 40 weeks | Published human clinical trial (Tier 1)[17] |
| PIONEER 1 | 703 adults with type 2 diabetes | Oral | 3 mg, 7 mg, 14 mg | Once daily | 26 weeks | Published human clinical trial (Tier 1)[18] |
| Reported outside labels and trials | ||||||
| Real-world “sustained low dose” | 814 of 490,072 semaglutide-treated patients in a 29 million record network | Subcutaneous | 0.25 mg prescriptions only (at least three, spanning 6 months or more) | Not stated | 6 months or more | Published human observational research (Tier 2)[27] |
| Compounded semaglutide, FDA statements | Patients on compounded injectables | Subcutaneous, vials and syringes | FDA reports doses “beyond what is in the FDA-approved drug label” (amounts not stated) | Larger single doses, more frequent dosing | Faster titration | Regulator report[23] |
| “Microdose” lists | Compounded product, telehealth marketplace page | Subcutaneous | 0.05, 0.10, 0.15, 0.20 mg | Once weekly | 2 to 4 weeks, then 0.25 mg (per the page) | Community, vendor or clinic reported (Tier 6)[31] |
| Gray-market vial schedules | 5 mg and 10 mg vials of “research” powder | Subcutaneous, user-mixed | 0.25, 0.5, 1.0, 1.7, 2.4 mg steps, with unit counts that depend on water added | Once weekly | 4 weeks per step | Community, vendor or clinic reported (Tier 6); origin unclear[32][33][35] |
| “Sema” stacks with other peptides | Not applicable | Not applicable | Not consistently reported | Not consistently reported | Not consistently reported | No established or reliably sourced dosing information was identified |
Label rows paraphrase the dosage sections of the labels read for this page (Wegovy 05/2026, Ozempic 05/2026, Rybelsus 10/2025). Trial enrollment is as published. Rybelsus and Ozempic tablets share one label; the R1 and R2 formulations are not interchangeable milligram for milligram.[3]
Where these figures come from
Semaglutide is unusual: almost every number above traces to a label or a peer-reviewed paper. The unregulated numbers are the exception, and they mostly turn out to be copies of one label.
- Most-reported figures: 0.25 mg to start, 2.4 mg to maintain. Both come from the Wegovy label’s 16-week escalation (0.25, 0.5, 1, 1.7, then 2.4 mg), and 2.4 mg is the dose tested in STEP 1, STEP 2, STEP 5, SELECT and STEP TEENS.[1][7]
- Human clinical evidence: yes, from 0.5 mg weekly (SUSTAIN-6) to 7.2 mg weekly (STEP UP), and from 3 mg to 50 mg daily by mouth.[10][16][12]
- Animal evidence: rodent studies exist, but the abstracts opened for this page give no dose figures, so none appear here, and no animal amount converts to a human one.[42]
- Practitioner figures: clinicians describe click counting on pens and stretching maintenance doses to about every 10 days, without amounts or trials.[28][29]
- Community and vendor figures: vial schedules and microdose lists exist on telehealth, vendor and “wiki” pages. Their step doses (0.25, 0.5, 1.0, 1.7, 2.4 mg) are the Wegovy label steps applied to a vial. Only the unit counts differ, and those depend entirely on how much water is added.[32][33][34][35]
- Copycat risk: one wiki page labels its 5 mg vial schedule a “community protocol” built from “500 community reports” without naming any report.[32] Count those pages once, as copies of the label.
- Weight-based conversions: none are used. Every label and trial dose above is a fixed milligram amount, not a milligram-per-kilogram dose.
The deeper entry for the molecule is the semaglutide research entry. The Atlas keeps a plainer semaglutide medication page for brand names and approvals.
Detailed human data
Injection labels side by side: Ozempic and Wegovy
Same molecule, different labels. Ozempic is built for blood sugar and stops at 2 mg. Wegovy is built for weight and risk reduction and climbs to 2.4 mg, with an upper allowance of 7.2 mg. The Atlas explains the practical differences in Ozempic vs Wegovy.
Swipe the table sideways to see every column.
| Step | Wegovy injection[1] | Ozempic[2] |
|---|---|---|
| Weeks 1 to 4 | 0.25 mg (starting dosage) | 0.25 mg for 4 weeks |
| Weeks 5 to 8 | 0.5 mg | 0.5 mg after 4 weeks on 0.25 mg |
| Weeks 9 to 12 | 1 mg | 1 mg may follow after at least 4 weeks on 0.5 mg |
| Weeks 13 to 16 | 1.7 mg | 2 mg may follow after at least 4 weeks on 1 mg |
| Week 17 onward | Maintenance by indication (see below) | Maintenance 0.5, 1 or 2 mg, based on glycemic control |
| Maintenance, weight (adults) | 1.7 mg or 2.4 mg (2.4 mg recommended). Up to 7.2 mg if 2.4 mg tolerated at least 4 weeks and more weight reduction is clinically indicated | Not labeled for weight management |
| Maintenance, other uses | Heart risk: 2.4 mg recommended or 1.7 mg. Age 12 and up, weight: 2.4 mg recommended or 1.7 mg. MASH: 2.4 mg | Kidney disease with type 2 diabetes: 1 mg after at least 4 weeks on 0.5 mg |
| Maximum | 7.2 mg once weekly (adults, weight) | 2 mg once weekly |
| If a dose is not tolerated | “Consider delaying dosage escalation for 4 weeks” | Not stated in the dosage text read |
Wegovy: label revised 05/2026 (the DailyMed copy shows 6/2026). Ozempic: label revised 05/2026. Quoted phrases are the label’s own wording.
Tablet labels: Wegovy, Rybelsus and Ozempic tablets
Tablets climb in 30-day steps. The weight tablet (Wegovy) and the diabetes tablets (Rybelsus and Ozempic tablets) are separate products with separate strengths.
Swipe the table sideways to see every column.
| Days | Wegovy tablets[1] | Rybelsus, formulation R1[3] | Ozempic tablets, formulation R2[3] |
|---|---|---|---|
| 1 to 30 | 1.5 mg | 3 mg (label: not effective for glycemic control) | 1.5 mg (label: not effective for glycemic control) |
| 31 to 60 | 4 mg | 7 mg | 4 mg |
| 61 to 90 | 9 mg | Keep 7 mg, or 14 mg if more glycemic control is needed | Keep 4 mg, or 9 mg if more glycemic control is needed |
| Day 91 onward | 25 mg maintenance | Continue chosen dose | Continue chosen dose |
The Wegovy tablet label also says to consider the 1.7 mg weekly injection if 25 mg is not tolerated. The Rybelsus label says its two formulations are not interchangeable mg for mg and should not be used together.[3]
Pen strengths exactly as labeled
Prefilled pens do not use “units” or syringes. The label dose is the amount the pen delivers. The label lists these presentations.
Swipe the table sideways to see every column.
| Product | Presentation (as labeled) | What it delivers |
|---|---|---|
| Wegovy pens | 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, 2.4 mg/0.75 mL, 7.2 mg/0.75 mL (Wegovy HD)[1] | One single-dose pen per weekly dose |
| Wegovy syringes | 0.25, 0.5, 1, 1.7 and 2.4 mg (the 7.2 mg strength is a pen only)[1] | One syringe per weekly dose |
| Ozempic pen, 2 mg/3 mL (0.68 mg/mL) | Multi-dose pen[2] | Four 0.25 mg doses and two 0.5 mg doses, or four 0.5 mg doses |
| Ozempic pen, 4 mg/3 mL (1.34 mg/mL) | Multi-dose pen[2] | Four 1 mg doses |
| Ozempic pen, 8 mg/3 mL (2.68 mg/mL) | Multi-dose pen[2] | Four 2 mg doses |
Weight-loss trials, with the estimand stated
An estimand is the exact question a trial’s number answers. The “treatment policy” version counts everyone as randomized, whether or not they kept taking the drug. The “trial product” or “efficacy” version asks what happened while people stayed on it. The second always looks better, so compare like with like.
Swipe the table sideways to see every column.
| Trial and dose | Weeks | Drug arm | Placebo | Difference (95% CI) | Estimand as published |
|---|---|---|---|---|---|
| STEP 1, 2.4 mg weekly[7] | 68 | -14.9% | -2.4% | -12.4 points (-13.4 to -11.5) | Regardless of discontinuation or rescue |
| STEP 2, 2.4 mg weekly, type 2 diabetes[8] | 68 | -9.6% | -3.4% | -6.2 points (-7.3 to -5.2) | Intention to treat. The 1.0 mg arm’s weight result is not in the abstract |
| STEP 5, 2.4 mg weekly[9] | 104 | -15.2% | -2.6% | -12.6 points (-15.3 to -9.8) | Regardless of discontinuation or rescue |
| STEP UP, 7.2 mg weekly[10] | 72 | -18.7% | -3.9% | -14.8 points (-16.2 to -13.4) | Treatment policy |
| STEP UP, 2.4 mg arm[10] | 72 | -15.6% | -3.9% | 7.2 mg versus 2.4 mg: -3.1 points (-4.7 to -1.6) | Treatment policy |
| STEP UP T2D, 7.2 mg weekly[11] | 72 | -13.2% | -3.9% | -9.3 points (-11.0 to -7.7) | Reported in the abstract without a named estimand |
| OASIS 1, oral, escalated to 50 mg daily[12] | 68 | -15.1% | -2.4% | -12.7 points (-14.2 to -11.3) | Regardless of discontinuation or other weight drugs |
| OASIS 4, oral, 25 mg daily[13] | 64 | -13.6% | -2.2% | -11.4 points (-13.9 to -9.0) | Not named in the abstract |
| STEP TEENS, 2.4 mg weekly, age 12 to under 18[20] | 68 | BMI -16.1% | BMI +0.6% | -16.7 points (-20.3 to -13.2) | Change in BMI, not body weight |
Company-reported extras, not peer reviewed: Novo Nordisk gave 20.7% mean loss for 7.2 mg in STEP UP under the efficacy estimand, and 16.6% for the 25 mg tablet in OASIS 4 when treatment was adhered to.[4][5] Different trials enrolled different people, so rows are not a head-to-head ranking.
What the dose response shows
Going from 2.4 mg to 7.2 mg added 3.1 percentage points of weight loss in STEP UP (18.7% versus 15.6%), and more people reached 20% or 25% loss: odds ratios of 1.8 and 2.4 versus 2.4 mg.[10] The cost showed up in side effects. Gastrointestinal events occurred in 70.8% on 7.2 mg, 61.2% on 2.4 mg and 42.8% on placebo, and dysaesthesia (odd skin sensations such as tingling or burning) in 22.9%, 6.0% and 0.5%.[10] In people with type 2 diabetes the same pattern held: 18.9% had dysaesthesia on 7.2 mg versus 4.9% on 2.4 mg and none on placebo.[11]
Lower on the ladder, extra milligrams buy less. In SUSTAIN FORTE, 2.0 mg beat 1.0 mg for HbA1c (a blood sugar marker) by 0.23 points on the trial-product estimand and 0.18 points on the treatment-policy estimand, with about 0.8 to 0.9 kg more weight loss.[17] The direction is the same in every dose-comparison trial here: more drug, a bit more effect, more stomach side effects. Nothing in this evidence picks a best dose for a given person.
Swipe the table sideways to see every column.
| Trial | Doses compared | Result | Estimand |
|---|---|---|---|
| SUSTAIN FORTE[17] | 2.0 mg versus 1.0 mg weekly, 40 weeks | HbA1c change -2.2 versus -1.9 points; weight -6.9 versus -6.0 kg | Trial product |
| SUSTAIN FORTE[17] | Same trial | HbA1c change -2.1 versus -1.9 points; weight -6.4 versus -5.6 kg | Treatment policy |
| PIONEER 1[18] | Oral 3 mg, 7 mg, 14 mg daily, 26 weeks | Placebo-adjusted HbA1c: -0.6, -0.9, -1.1 points. Weight: -0.1, -0.9, -2.3 kg | Treatment policy |
| PIONEER 1[18] | Same trial | Placebo-adjusted HbA1c: -0.7, -1.2, -1.4 points. Weight: -0.2, -1.0, -2.6 kg | Trial product |
Outcome trials: which dose was used
These trials asked about heart attacks, kidneys and liver rather than weight. The useful dosing fact is the dose each one tested.
Swipe the table sideways to see every column.
| Trial | Dose and route | Participants | Main result |
|---|---|---|---|
| SELECT[14] | 2.4 mg weekly, subcutaneous | 17,604 adults, cardiovascular disease, BMI 27 or more, no diabetes | Heart attack, stroke or cardiovascular death: 6.5% versus 8.0% on placebo (hazard ratio 0.80, 0.72 to 0.90). Stopped for adverse events: 16.6% versus 8.2% |
| FLOW[15] | 1.0 mg weekly, subcutaneous | 3,533 adults, type 2 diabetes and chronic kidney disease | Major kidney events 24% lower (hazard ratio 0.76, 0.66 to 0.88) |
| SUSTAIN-6[16] | 0.5 mg or 1.0 mg weekly, subcutaneous | 3,297 adults, type 2 diabetes, high cardiovascular risk | Primary outcome 6.6% versus 8.9% (hazard ratio 0.74, 0.58 to 0.95) |
| PIONEER 6[19] | Oral once daily (dose not stated in the abstract) | 3,183 adults, type 2 diabetes, high cardiovascular risk | Primary outcome 3.8% versus 4.8% (hazard ratio 0.79, 0.57 to 1.11), shown to be non-inferior |
| ESSENCE (interim)[21] | 2.4 mg weekly, subcutaneous | 1,197 adults with MASH and fibrosis stage 2 or 3; first 800 analyzed at week 72 | MASH resolution without worse fibrosis: 62.9% versus 34.3% |
Oral versus injectable at the dose level
The labeled weight doses are 25 mg daily by mouth or 2.4 mg weekly by injection, and the label gives a switching rule: start the 25 mg tablet one week after the last 2.4 mg injection, and start 2.4 mg by injection the day after the last 25 mg tablet.[1] OASIS 4 gave -13.6% at week 64 and STEP 1 gave -14.9% at week 68, in different trials.[13][7] A 2026 indirect comparison of those two trials found a small numerical edge for injection (1.01 percentage points under treatment regimen, 95% CI -1.61 to 3.63) and called the efficacy comparable.[22] It is not a head-to-head trial. The Atlas covers the practical tradeoffs in pill or shot.
Animal research amounts
Semaglutide has been studied in mice and rats, including work from Novo Nordisk scientists on how it acts in the brain.[42] The abstracts opened for this page do not state a dose, so no amounts are tabulated.
Swipe the table sideways to see every column.
| Objective | Species | Amount | Evidence category |
|---|---|---|---|
| Brain pathways of weight loss | Mouse and rat | Not consistently reported in the abstract | Published animal research (Tier 3)[42] |
Animal doses are written in per-kilogram terms and cannot be turned into human doses by multiplication. I found no case of a dog or rodent semaglutide amount being copied into a human protocol. If you see one, treat it as a red flag, because no source for the conversion exists.
Compounded, microdose and vial protocols
None of this material is clinical evidence. It is here because people search for it, and because the numbers cause real harm when they are misread. Every figure below is stated as the source states it.
Compounded semaglutide: what the FDA says about doses
Compounded drugs are made by pharmacies and are not FDA approved. The FDA says it does not review them for safety, effectiveness or quality before they are sold.[23] Its page lists 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, counted as of May 31, 2026, on a page current as of October 1, 2026. The FDA says these are underreported, and a report count cannot show how common a problem is.[23] The Atlas explains how to read them in its guide to FDA safety reports, and the basics of the category in compounded vs brand and what a 503A pharmacy is.
The dosing problems the FDA describes are concrete. In its July 26, 2024 alert, most reports involved patients drawing more than prescribed from a multiple-dose vial. In several, patients told to draw 5 units (0.05 mL) on a U-100 insulin syringe drew 50 units instead, an overdose of five to twenty times the intended amount. Providers also made conversion mistakes: one intended 0.25 mg (5 units) and prescribed 25 units, and another prescribed 20 units instead of 2 units for three patients.[24] The alert notes that FDA-approved semaglutide is dosed in milligrams at standard concentrations and comes only as prefilled pens, while compounders offer varying concentrations, sometimes several from one compounder.[24] A poison-center case series reached the same conclusion: two of three patients made 10-fold self-administration errors, and one dosed in milliliters and units rather than milligrams.[26]
The FDA also reports prescriptions for “doses beyond what is in the FDA-approved drug label,” meaning larger single doses, more frequent dosing or faster titration, and it asks prescribers to be vigilant.[23] It gives no amounts for those, so I do not either. For the policy backdrop, see our note on 503A enforcement discretion.
What “microdosing” means (it means several things)
There is no standard definition. Reviewing the sources shows at least five different practices under one name. The Atlas page GLP-1 microdosing: what the evidence does and does not show found no label, randomized trial or registered trial that supports it, and a ClinicalTrials.gov search it ran on October 23, 2026 returned no registered study using the term.[41]
Swipe the table sideways to see every column.
| Practice | Amount or schedule as reported | Source and type | Evidence category |
|---|---|---|---|
| Staying on the 0.25 mg strength | At least three separate 0.25 mg prescriptions spanning 6 months or more. Matched 12-month weight change -2.2% (semaglutide) versus -5.5% (tirzepatide 2.5 mg). The authors say this pattern “may overlap with, but does not establish, intentional microdosing” | Murugadoss et al., Biol Methods Protoc 2026, electronic health records[27] | Published human observational research (Tier 2) |
| Sub-starting doses | 0.05, 0.10, 0.15, 0.20 mg weekly; 0.1 mg called “most commonly prescribed”; 2 to 4 weeks before moving to 0.25 mg. The page claims 4 to 8% loss over 6 months at 0.1 mg while stating that no randomized trial has tested doses below 0.25 mg | A telehealth marketplace’s article (commercial page, May 2026)[31] | Community, vendor or clinic reported (Tier 6) |
| Slow climb to the label dose | Start at 0.25 mg and increase to 2.4 mg over 20 weeks, sold as a “microdosing” approach for compounded semaglutide | Trade press report on Noom, May 21, 2025 (secondary source)[30] | Community, vendor or clinic reported (Tier 6) |
| Pen click counting | Dialing fewer clicks on an Ozempic, Victoza or Saxenda pen than the dose the pen is labeled for. No clicks-per-dose conversion is published. Novo Nordisk “does not recommend using click counting,” and the safety group notes “no studies that support this dosing method.” Wegovy pens are fixed-dose, single-use devices, so clicks cannot be counted | ISMP Consumer Med Safety, January 6, 2025[28] | Practitioner and safety-organization report |
| Stretching the interval | Spreading maintenance doses from weekly to “about every 10 days”; no amounts. The author of the essay does not call it microdosing | Dushay, STAT First Opinion, May 29, 2026[29] | Practitioner reported (Tier 5) |
The evidence base is a single observational study that used repeat 0.25 mg prescriptions as a proxy for sustained low dosing, plus marketing. Murugadoss et al. found 814 of 490,072 semaglutide-treated patients met their strict criterion, and they call for prospective studies.[27] The Atlas also reads this study and lists its limits in its microdosing guide.
Gray-market “research” vials: the schedules as sources state them
Semaglutide is also sold as freeze-dried powder labeled for research. The FDA says it has warned companies selling semaglutide products “falsely labeled ‘for research purposes’ or ‘not for human consumption'” that were “sold directly to consumers for human use with dosing instructions,” and urges consumers not to buy them because their quality is unknown.[23] The instructions that follow exist anyway, so here is what they say.
Every schedule found is the Wegovy escalation (0.25, 0.5, 1.0, 1.7, 2.4 mg, four weeks each) applied to a vial. The Wegovy label itself describes only prefilled pens and syringes, never a vial.[1] What changes between pages is the water added, which sets the concentration, which sets the number of syringe units.
Swipe the table sideways to see every column.
| Source (type) | Vial and water | Concentration | 0.25 mg shown as | Other doses shown |
|---|---|---|---|---|
| Peptide Protocol Wiki 5 mg calculator (educational site; labels it a “community protocol” from “500 community reports”)[32] | 5 mg + 2 mL (default). Alternative: 5 mg + 1 mL | 2.50 mg/mL. Alternative: 5.00 mg/mL | 10 units (0.100 mL). Alternative: 5 units (0.050 mL) | Default weekly dose 250 mcg. The page itself warns of “dosing errors due to concentration confusion” |
| PeptidesExplorer how-to (educational blog, June 29, 2026)[33] | 5 mg + 1 mL, 2 mL (default) or 2.5 mL | 5.0, 2.5 or 2.0 mg/mL | 5, 10 or 12.5 units | 0.5 mg: 10, 20, 25 units. 1.0 mg: 20, 40, 50. 1.7 mg: 34, 68, 85. 2.4 mg: 48, 96, 120 (page: “more than a single 100-unit syringe holds”) |
| PeptidesExplorer dosage chart (educational blog, March 6, 2026)[34] | 10 mg + 1 mL, or 10 mg + 2 mL; 5 mg + 1 mL or 2 mL | 10, 5, 5 or 2.5 mg/mL | 2.5, 5, 5 or 10 units | Says “most compounders use 1 mL for a 5 mg vial.” Gives doses-per-vial counts |
| Research-peptide seller’s help-center article (vendor, February 26, 2026)[35] | 10 mg + 2.0 mL | About 5.0 mg/mL (“1 unit about 50 mcg”) | 5 units (0.05 mL) | 0.5 mg: 10 units. 1 mg: 20. 1.7 mg: 34. 2.4 mg: 48 units (0.48 mL). Same page says products are “not intended for human consumption” |
| Telehealth marketplace microdose article (commercial, May 2026)[31] | Concentrations only | 2.5 or 5 mg/mL | 10 units at 2.5 mg/mL | 0.10 mg: 4 units at 2.5 mg/mL, 2 units at 5 mg/mL |
None of these pages cites a study for its mixing or unit numbers. The arithmetic they share is units = dose in mg divided by concentration in mg/mL, times 100.
That shared arithmetic answers two common questions. How many units is 0.25 mg? There is no single answer, because units measure volume and volume depends on concentration. The table above shows 2.5 to 12.5 units for the same 0.25 mg. How much water goes in a 5 mg vial? The sources above use 1 mL, 2 mL or 2.5 mL, and each choice produces a different unit count. No regulator publishes a vial recipe, because approved semaglutide does not come as a vial.[24] Multi-dose vials are, per the FDA, to be discarded 28 days after first use.[23] Our reconstitution calculator does this math for any numbers you type in, with no presets, and our guides cover units versus milligrams, reading an insulin syringe, how water volume sets concentration and bacteriostatic versus sterile water. Those are measurement lessons, not endorsements of any vial schedule.

Escalation, missed doses, timing and routes
The labels are specific about what to do when things go sideways, and the wording differs by product.
Swipe the table sideways to see every column.
| Topic | Wegovy injection[1] | Ozempic[2] | Tablets[1][3] |
|---|---|---|---|
| One missed dose | If the next dose is “more than 2 days away, administer WEGOVY injection as soon as possible.” If “less than 2 days away,” do not give it and resume on the regular day | “Administer OZEMPIC as soon as possible within 5 days after the missed dose.” After more than 5 days, skip it and give the next dose on the regular day | “Skip the missed dose and take the next dose the following day” |
| Two or more missed | “Resume dosing as scheduled or, if needed, reinitiate WEGOVY injection and follow the dosage escalation schedule,” which may reduce gastrointestinal reactions | Not stated in the text read | Not applicable |
| Timing | Same day each week, any time of day, with or without meals; abdomen, thigh or upper arm | Same pattern; the day can be changed if doses stay at least 2 days (more than 48 hours) apart | Morning, empty stomach, up to 4 ounces of plain water, swallow whole; wait at least 30 minutes before food, drink or other oral medicines |
| Not tolerated | “Consider delaying dosage escalation for 4 weeks” | Not stated in the text read | Wegovy tablets: consider delaying escalation. If 25 mg is not tolerated, consider the 1.7 mg injection |
| Switching forms | To tablets: start 25 mg one week after the last 2.4 mg injection | Rybelsus label: from Ozempic 0.5 mg weekly, start tablets one week after the last injection (7 or 14 mg for R1, 4 or 9 mg for R2). No guidance is given for Ozempic 0.25, 1 or 2 mg | From Wegovy 25 mg tablets: start 2.4 mg injection the day after the last tablet |
Routes: the approved routes are subcutaneous injection (weekly) and swallowed tablets (daily). No nasal, sublingual or topical semaglutide is approved. For how the form changes the dose, see the guide to injected, oral and nasal routes. A 2026 indirect comparison describes systemic exposure from the oral and injected forms as comparable, which is why very different milligram doses can do similar work.[22]
For what happens after you stop or change course, the Atlas has pages on weight regain after stopping, side effects week by week and switching between brands.
Reported amounts say nothing about what follows when a GLP-1 drug is stopped. One observational Italian cohort reported a death hazard ratio of 4.81 for time off the drug, a figure its authors say is too large to be the drug alone; the analysis of the GLP-1 discontinuation study sets out the limits.
Combinations and stacks
Swipe the table sideways to see every column.
| Type | What exists | Source |
|---|---|---|
| Formally studied | CagriSema: cagrilintide 2.4 mg plus semaglutide 2.4 mg, once weekly, 68 weeks, in adults with obesity and type 2 diabetes (REDEFINE 2). Mean weight change -13.7% versus -3.4% on placebo, treatment-policy estimand. Not approved; Novo Nordisk filed with the FDA in December 2025 per the Atlas record[44] | Published human clinical trial (Tier 1)[38] |
| Label position | Wegovy’s label says combining it with other semaglutide products or any other GLP-1 receptor agonist is not recommended | Prescribing information[1] |
| Mechanistically plausible | No sourced protocol identified | No established or reliably sourced dosing information was identified |
| Practitioner reported | None identified | Not consistently reported |
| Community reported | A telehealth marketplace page on semaglutide plus BPC-157 gives no amounts, frequency or duration, says its evidence base is “preclinical research, small human studies, and community-reported outcomes,” and says it drew on 5,126 Reddit threads. A peptide-protocol directory lists CagriSema as its only stack containing semaglutide and gives no amounts, while contradicting itself on whether any stack has been trial-tested | Community, vendor or clinic reported (Tier 6)[39][40] |
Popularity of a stack is not evidence it is safe or works. See CagriSema for the one combination with trial data.
Side effects, quality and sourcing risks as reported
Side effects in the trials
Nausea, vomiting, diarrhea and constipation lead the list. Gastrointestinal events occurred in 63.5% on 2.4 mg and 57.5% on 1.0 mg versus 34.3% on placebo in STEP 2,[8] in 80% versus 46% with oral 50 mg in OASIS 1,[12] and in 74.0% versus 42.2% with oral 25 mg in OASIS 4.[13] In STEP 1, 4.5% on semaglutide stopped because of gastrointestinal events versus 0.8% on placebo.[7] SELECT recorded permanent discontinuation for adverse events in 16.6% versus 8.2%.[14] SUSTAIN-6 found more retinopathy complications on semaglutide (hazard ratio 1.76, 1.11 to 2.78) in people with diabetes,[16] and 5 of 133 adolescents on semaglutide had gallstones versus none on placebo in STEP TEENS.[20] The labels carry a boxed warning about thyroid tumors seen in rodents, per the Atlas summary of the label.[43] Higher doses carry more: see the STEP UP dysesthesia figures above.
Compounded and gray-market product quality
- FDA warnings: counterfeit Ozempic is in the U.S. supply, and the FDA says the compounding of salt forms such as semaglutide sodium and semaglutide acetate, which are different active ingredients from the approved drugs, has no lawful basis it is aware of.[23]
- Test purchases: a 2024 research letter in JAMA Network Open bought from six “not recommended or rogue” online sellers. Semaglutide was present in every sample, but purity was 7 to 14 percent against 99 percent advertised, measured content exceeded the labeled amount, and one sample had elevated endotoxin. Genuine Ozempic scored 22 on a quality checklist, the purchases 8 or 9.[36]
- Independent peptide testing: Finnrick Analytics, a US peptide testing service, reports 338 semaglutide samples from 57 vendors between December 17, 2024 and July 1, 2026. Purity typically ran 98.34 to 99.99 percent, but measured quantity “typically diverges by up to +/-38%” from the advertised amount at the 95th percentile, and one 10 mg-labeled sample measured 4.79 mg. Some samples were vendor-submitted, and the service notes it issued corrections, including a possible tirzepatide and semaglutide mix-up.[37]
Read those two together. Even where purity looks fine, the amount in the vial can be far off, and that is the number every unit calculation depends on. A vial labeled 10 mg that holds 4.79 mg doubles every dose computed from the label.
Regulatory and development status
As checked for this page on November 2, 2026, these semaglutide products are FDA approved:
- Ozempic injection: type 2 diabetes, plus heart and kidney indications. Label revised 05/2026.[2]
- Wegovy injection: weight reduction (adults and age 12 and up), cardiovascular risk reduction and MASH (accelerated approval). Label revised 05/2026.[1]
- Wegovy HD (7.2 mg): approved in the U.S. on March 19, 2026 for adults, the first GLP-1 approved under the FDA Commissioner’s National Priority Voucher pilot, supplied as a single-dose pen. Novo Nordisk expected a U.S. launch in April 2026.[4] See Wegovy HD on the Atlas.
- Wegovy tablets (25 mg maintenance): approved December 22, 2025, the first oral GLP-1 for weight management.[5]
- Rybelsus and Ozempic tablets: type 2 diabetes. The second Rybelsus formulation was renamed Ozempic tablets in a January 2026 label revision announced February 4, 2026; strengths 1.5, 4 and 9 mg.[6] Novo Nordisk is retiring the Rybelsus name in the U.S.[43]
Compounding: the FDA declared the semaglutide injection shortage resolved on February 21, 2025. Enforcement discretion for state-licensed pharmacies ended after an April 24, 2025 court denial, and the date given for outsourcing facilities was May 22, 2025.[25] Rules and court cases keep moving, so check the FDA pages. CagriSema is not approved.[38][44]

What is not public or not answered
- Any randomized trial of “microdosing” or doses below the label starting dose. None was found.[41]
- The 1.0 mg arm’s weight result in STEP 2 and the 2.4 mg arm’s weight result in STEP UP T2D, which the abstracts opened here do not give.
- Any dose above 7.2 mg weekly, or a head-to-head trial of the 25 mg tablet against 2.4 mg injection.
- The origin of the “500 community reports” behind one wiki’s vial protocol.
- Whether gray-market vials contain what their labels say; test data are small, partly vendor-submitted and mixed.
- Any lawful basis for a vial schedule: no regulator has published one.
- A sourced, tested semaglutide stack outside CagriSema.
Frequently asked questions
What is the semaglutide dosage chart?
It depends on the product. Wegovy injection: 0.25 mg for 4 weeks, 0.5 mg for 4, 1 mg for 4, 1.7 mg for 4, then maintenance 1.7 or 2.4 mg, with 7.2 mg allowed for some adults. Ozempic: 0.25 mg for 4 weeks, then 0.5 mg, with 1 mg and 2 mg available. Wegovy tablets: 1.5, 4, 9, then 25 mg daily, 30 days each until day 91. See the tables above, which follow the labels.
What is the semaglutide dosage for weight loss?
The Wegovy label’s maintenance is 1.7 mg or 2.4 mg once weekly, with 2.4 mg recommended and up to 7.2 mg for adults who tolerate 2.4 mg for at least 4 weeks and need more. The 25 mg tablet is the oral option. In STEP 1, 2.4 mg gave -14.9% versus -2.4% on placebo at 68 weeks.
How many units is 0.25 mg of semaglutide?
There is no fixed number. Units measure volume, so the answer depends on the vial’s concentration. The same 0.25 mg appears as 2.5, 5, 10 or 12.5 units depending on the mix. Pens do not use units at all, and the FDA documented overdoses of five to twenty times when people confused units with milligrams.
How much water goes in a 5 mg semaglutide vial?
No label or regulator gives a vial recipe, because approved semaglutide comes in prefilled pens. Online sources use 1 mL, 2 mL or 2.5 mL of water for a 5 mg vial, which gives 5.0, 2.5 or 2.0 mg/mL, and each changes the unit count. None of those pages cites a study.
What is the difference between the Ozempic and Wegovy dose?
Both start at 0.25 mg weekly and climb every 4 weeks. Ozempic (diabetes) stops at 2 mg. Wegovy (weight, heart, liver) maintains at 1.7 or 2.4 mg and allows up to 7.2 mg. They are separate products with separate labels and separate pen strengths.
What if I miss a semaglutide dose?
The labels differ. Wegovy injection: give it if the next dose is more than 2 days away, otherwise skip and resume the regular day. Ozempic: give it as soon as possible within 5 days, otherwise skip. Tablets: skip it and take the next dose the following day. This summarizes label text and is not advice for any person.
Is the semaglutide dose different for diabetes than for weight loss?
Yes. Ozempic’s range is 0.5 to 2 mg weekly for blood sugar. Wegovy’s is 1.7 to 2.4 mg, with up to 7.2 mg, for weight. The oral diabetes tablets (Rybelsus, Ozempic tablets) use 3, 7 or 14 mg or 1.5, 4 or 9 mg, and the weight tablet uses up to 25 mg.
Is oral semaglutide the same as the injection?
Same drug, different product. The labeled weight doses are 25 mg daily by mouth or 2.4 mg weekly by injection, the tablet has strict morning and water rules, and the label sets a switching rule. OASIS 4 gave -13.6% at 64 weeks and STEP 1 gave -14.9% at 68 weeks, in different trials.
Does microdosing semaglutide work?
That has not been tested. No label, randomized trial or registered trial supports microdosing, and the main study is an observational look at people who kept filling 0.25 mg prescriptions. The FDA has documented dosing errors with compounded vials.
Can semaglutide be combined with other peptides?
Only CagriSema (with cagrilintide, both 2.4 mg weekly) has trial data, and it is not approved. The Wegovy label does not recommend combining with other GLP-1 receptor agonists. No sourced stack protocol was found.
Bottom line
Semaglutide has unusually solid published dosing: labels for Ozempic, Wegovy, Wegovy HD and the tablets, and trials that cover 0.5 to 7.2 mg weekly and 3 to 50 mg daily. The strongest evidence says 2.4 mg weekly gave about 15% loss over 68 weeks, 7.2 mg added about 3 points in STEP UP at the cost of more digestive and skin-sensation effects, and oral 25 mg is in the same range. What is merely reported online is vial mixing, microdose lists and stacks, and most of it is the Wegovy label recycled with unit counts that swing fourfold with the water added. What remains speculative is whether lower doses preserve benefit, and no trial answers it. The FDA’s concerns are real: dosing errors, doses beyond label, counterfeit and mislabeled product. Pick the number off the label for the product in your hand, not off a vial chart.
Keep reading
Sources
- Novo Nordisk. Wegovy (semaglutide) injection and tablets: prescribing information. U.S. Food and Drug Administration. Revised 05/2026 (the DailyMed copy shows 6/2026). One label covers the injection and the tablets. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s031lbl218316s003lbl.pdf Prescribing information (label)
- Novo Nordisk. Ozempic (semaglutide) injection: prescribing information. U.S. Food and Drug Administration. Revised 05/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf Prescribing information (label)
- Novo Nordisk. Rybelsus (semaglutide) tablets: prescribing information, covering formulations R1 and R2. U.S. Food and Drug Administration. Revised 10/2025. The R2 formulation was later renamed Ozempic tablets, so a newer label may exist. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051s024%2Cs028s029lbl.pdf Prescribing information (label)
- Novo Nordisk. Wegovy HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss. Company announcement No. 19/2026. 19 March 2026. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916516 Company announcement (sponsor-reported, not peer reviewed)
- Novo Nordisk A/S. Wegovy pill approved in the US as first oral GLP-1 for weight management. Company announcement, Bagsvaerd, Denmark. 22 December 2025. Reproduced by a financial news service. https://www.placera.se/pressmeddelanden/novo-nordisk-b-novo-nordisk-a-s-wegovy-pill-approved-in-the-us-as-first-oral-glp-1-for-weight-management-20251222 Company announcement (sponsor-reported, not peer reviewed)
- Epocrates. Rybelsus rebranded as Ozempic pill. Reports Novo Nordisk’s 4 February 2026 announcement and a January 2026 package insert revision; strengths 1.5, 4 and 9 mg. https://epocrates.com/online/article/rybelsus-rebranded-as-ozempic-pill Trade press, secondary source
- Wilding et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. Published 10 February 2021. doi:10.1056/NEJMoa2032183. https://pubmed.ncbi.nlm.nih.gov/33567185/ Published human clinical trial (Tier 1). PMID 33567185.
- Davies et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. Published 2 March 2021. doi:10.1016/S0140-6736(21)00213-0. https://pubmed.ncbi.nlm.nih.gov/33667417/ Published human clinical trial (Tier 1). PMID 33667417.
- Garvey et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. Published 10 October 2022. doi:10.1038/s41591-022-02026-4. https://pubmed.ncbi.nlm.nih.gov/36216945/ Published human clinical trial (Tier 1). PMID 36216945.
- Wharton et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963. Published 14 September 2025. doi:10.1016/S2213-8587(25)00226-8. https://pubmed.ncbi.nlm.nih.gov/40961952/ Published human clinical trial (Tier 1). PMID 40961952.
- Lingvay et al. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):935-948. Published 14 September 2025. doi:10.1016/S2213-8587(25)00225-6. https://pubmed.ncbi.nlm.nih.gov/40961953/ Published human clinical trial (Tier 1). PMID 40961953.
- Knop et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705-719. Published 26 June 2023. doi:10.1016/S0140-6736(23)01185-6. https://pubmed.ncbi.nlm.nih.gov/37385278/ Published human clinical trial (Tier 1). PMID 37385278.
- Wharton et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025;393(11):1077-1087. Published 18 September 2025. doi:10.1056/NEJMoa2500969. https://pubmed.ncbi.nlm.nih.gov/40934115/ Published human clinical trial (Tier 1). PMID 40934115.
- Lincoff et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. Published 11 November 2023. doi:10.1056/NEJMoa2307563. https://pubmed.ncbi.nlm.nih.gov/37952131/ Published human clinical trial (Tier 1). PMID 37952131.
- Perkovic et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. Published 24 May 2024. doi:10.1056/NEJMoa2403347. https://pubmed.ncbi.nlm.nih.gov/38785209/ Published human clinical trial (Tier 1). PMID 38785209.
- Marso et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. Published 15 September 2016. doi:10.1056/NEJMoa1607141. https://pubmed.ncbi.nlm.nih.gov/27633186/ Published human clinical trial (Tier 1). PMID 27633186.
- Frias et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9(9):563-574. Published 21 July 2021. doi:10.1016/S2213-8587(21)00174-1. https://pubmed.ncbi.nlm.nih.gov/34293304/ Published human clinical trial (Tier 1). PMID 34293304.
- Aroda et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724-1732. Published 11 June 2019. doi:10.2337/dc19-0749. https://pubmed.ncbi.nlm.nih.gov/31186300/ Published human clinical trial (Tier 1). PMID 31186300.
- Husain et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (PIONEER 6). N Engl J Med. 2019;381(9):841-851. Published 11 June 2019. doi:10.1056/NEJMoa1901118. https://pubmed.ncbi.nlm.nih.gov/31185157/ Published human clinical trial (Tier 1). PMID 31185157.
- Weghuber et al. Once-weekly semaglutide in adolescents with obesity (STEP TEENS). N Engl J Med. 2022;387(24):2245-2257. Published 2 November 2022. doi:10.1056/NEJMoa2208601. https://pubmed.ncbi.nlm.nih.gov/36322838/ Published human clinical trial (Tier 1). PMID 36322838.
- Sanyal et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE, interim analysis). N Engl J Med. 2025;392(21):2089-2099. Published 30 April 2025. doi:10.1056/NEJMoa2413258. https://pubmed.ncbi.nlm.nih.gov/40305708/ Published human clinical trial (Tier 1). PMID 40305708.
- Plotkin, Ivkovic, et al. Semaglutide 25 mg oral versus semaglutide 2.4 mg injectable: an indirect treatment comparison of weight loss. Diabetes Obes Metab. 2026;28(8):7237-7246. Published 1 June 2026. doi:10.1111/dom.70911. https://pubmed.ncbi.nlm.nih.gov/42225300/ Published indirect comparison of human trials (Tier 1 inputs, not head to head). PMID 42225300.
- U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Content current as of 1 October 2026; adverse event counts as of 31 May 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss Regulator report
- U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. 26 July 2024. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded Regulator report
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Content current as of 1 April 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize Regulator report
- Lambson et al. Administration errors of compounded semaglutide reported to a poison control center: case series. J Am Pharm Assoc. 2023;63(5):1643-1645. Published 29 June 2023. doi:10.1016/j.japh.2023.06.017. https://pubmed.ncbi.nlm.nih.gov/37392810/ Published human case series (Tier 2). PMID 37392810.
- Murugadoss, Venkatakrishnan, et al. Comparison of cardiometabolic benefits and tolerability in patients on sustained low doses of semaglutide or tirzepatide. Biol Methods Protoc. 2026;11(1):bpag048. Published 31 August 2026. doi:10.1093/biomethods/bpag048. https://pubmed.ncbi.nlm.nih.gov/42857675/ Published human observational research (Tier 2). PMID 42857675.
- ISMP Consumer Med Safety. Errors possible when microdosing (counting clicks) to dose weight loss medicines. 6 January 2025. https://www.consumermedsafety.org/safety-articles/errors-possible-when-microdosing-counting-clicks-to-dose-weight-loss-medicines Practitioner and safety-organization report (Tier 5)
- Dushay J. I’m a weight-loss doctor. Here’s why I worry about GLP-1 ‘microdoses.’ STAT First Opinion. 29 May 2026. https://www.statnews.com/2026/05/29/glp-1-microdose-popular-but-unsupported-by-evidence/ Practitioner reported (Tier 5), opinion essay
- Pharmaceutical Commerce. Noom to sell microdoses of Wegovy. 21 May 2025. https://www.pharmaceuticalcommerce.com/view/noom-to-sell-microdoses-wegovy Trade press, secondary source about a commercial program (Tier 6)
- Telehealth marketplace article on microdosing semaglutide. May 2026. Commercial page; link withheld. Community, vendor or clinic reported (Tier 6)
- Peptide Protocol Wiki. Semaglutide 5 mg reconstitution and dosing calculator. Undated educational calculator page; no external references cited. https://www.peptideprotocolwiki.com/tools/dosing-calculator/semaglutide-5mg Community protocol page (Tier 6); origin unclear
- Doctor H. How to reconstitute 5 mg semaglutide. PeptidesExplorer. 29 June 2026. https://peptidesexplorer.com/blog/how-to-reconstitute-5mg-semaglutide Educational blog (Tier 6); origin unclear
- PeptidesExplorer. Semaglutide dosage chart in mL and units. 6 March 2026. https://peptidesexplorer.com/blog/semaglutide-dosage-chart-ml Educational blog (Tier 6); origin unclear
- Research-peptide seller’s help-center article, semaglutide 10 mg dosage guide. 26 February 2026. Commercial page; link withheld. Community, vendor or clinic reported (Tier 6)
- Ashraf et al. Safety and risk assessment of no-prescription online semaglutide purchases. JAMA Netw Open. 2024;7(8):e2428280. Published 2 August 2024. https://pubmed.ncbi.nlm.nih.gov/39093567/ Published test-purchase study (Tier 2). PMID 39093567.
- Finnrick Analytics. Semaglutide product page: independent peptide test results, 17 December 2024 to 1 July 2026. Opened through the service’s demo address; a canonical address was not confirmed. https://demo.finnrick.com/products/semaglutide Independent testing service (Tier 6 data), partly vendor-submitted samples
- Davies et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). N Engl J Med. 2025;393(7):648-659. Published 22 June 2025. doi:10.1056/NEJMoa2502082. https://pubmed.ncbi.nlm.nih.gov/40544432/ Published human clinical trial (Tier 1). PMID 40544432.
- Telehealth marketplace article on semaglutide and BPC-157 together. 2026. Commercial page; link withheld. Community, vendor or clinic reported (Tier 6)
- Peptide Dosing Protocols. Peptide stacks directory (semaglutide appears only in its CagriSema entry). Mid-2026 per the site. https://www.peptidedosingprotocols.com/stacks Community protocol directory (Tier 6)
- The Weight Loss Atlas. GLP-1 microdosing: what the evidence does and does not show. Includes a ClinicalTrials.gov search run on 23 October 2026. https://theweightlossatlas.com/getting-started/glp-1-microdosing/ Secondary educational source
- Gabery et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6). Published 26 March 2020. doi:10.1172/jci.insight.133429. https://pubmed.ncbi.nlm.nih.gov/32213703/ Published animal research (Tier 3). PMID 32213703.
- The Weight Loss Atlas. Ozempic tablets brand page and semaglutide medication page (boxed warning summary; Rybelsus brand being retired in the U.S.). https://theweightlossatlas.com/brands/ozempic-tablets/ Secondary educational source
- The Weight Loss Atlas. CagriSema medication page (regulatory status). https://theweightlossatlas.com/medications/cagrisema/ Secondary educational source
Educational reference only, not medical advice. This page documents amounts printed on labels, studied in published research and reported online. It does not tell any reader what to take, and it does not say any amount is safe or effective. Talk to a qualified, licensed clinician about personal medical decisions.
A September 2026 mouse study in Nature is often cited in microdosing and longevity talk, but it used a dose that cut food intake by 24 percent. What the semaglutide lifespan study did and did not test goes through it.